Loading clinical trials...

COMPLETEDNA

Effects of Ultrasound and Infrared on Joint Pain and Movement in Hemophilia A Patients.

Comparative Effects of Ultrasound and Infrared on Pain, Range of Motion and Joint Health in Knee, Elbow and Ankle Joints in Patients With Hemophilia A: a Randomized Clinical Trial

NCT07116993•Danyal Ahmad

View on ClinicalTrials.gov

Summary

The study aims to compare the effectiveness of therapeutic ultrasound and infrared in managing hemarthrosis in patients with Hemophilia A, focusing on specific outcomes like joint pain, swelling, muscle atrophy, and range of motion.The main question to it is either one from both of the modalities are effective for hemophilia patients or not? comparison will be done to check the effectiveness of ultrasound and infrared on patients of both groups. participants will: 1. get the treatment according to their respective groups 2. Both groups were given 4 sessions for 4 weeks.

Detailed Description

The data collection was started by the consent of the participants through the consent form. Then we randomly divided the patients into Group A and Group B. Group A participants were given Ultrasound therapy for 10 minutes with intensity of 1.5 W/m2 along with the conventional physiotherapy as well as home plan. Group B participants were given Infrared therapy for 10 minutes with moderate intensity along with the conventional physiotherapy as well as home plan. Both groups were given 4 sessions for 4 weeks.

Eligibility

Age

All ages

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•1. Patients with hemophilia A (Eid \& Aly, 2015) .
•2. Who had the Bleeding frequency of atleast once per week (Eid \& Aly, 2015).
•3. Males with hemophilia A
•4. Irrespective of their therapeutic regime administered by their hematologists (Donoso-Úbeda, Meroño-Gallut, López-Pina, \& Cuesta Barriuso, 2020) .

Exclusion Criteria

•1. Patients who had surgical procedures (Eid \& Aly, 2015) .
•2. Patients who were suffering from co-morbidities along with Hemophilia A.
•3. Patients who had any other disability/deformity.
•4. Who were receiving other physiotherapy treatment (Donoso-Úbeda et al., 2020) .
•5. Who failed to sign the informed consent (Donoso-Úbeda et al., 2020)

Locations (1)

Danyal Ahmad

Sialkot, Punjab Province, Pakistan

Key Dates

Start Date

March 1, 2024

Primary Completion Date

March 30, 2024

Completion Date

June 15, 2024

Last Updated

August 12, 2025

Enrollment

ACTUAL participants

Conditions

Hemophilia A

Interventions

theraputic ultrasound

DEVICE

infrared radiation

DEVICE

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206

Hemophilia A

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449

Hemophilia A

View study

RECRUITING

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Ultrasound and Infrared on Joint Pain and Movement in Hemophilia A Patients.

Inclusion Criteria

Exclusion Criteria

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

National Longitudinal Cohort of Hematological Diseases

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Home Monitoring in Hemophilia a

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A